Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Resverlogix Establishes Clinical & Scientific Advisory Board

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
Dr. Bengt Winblad appointed Chairman of the clinical & scientific advisory board.

Resverlogix Corp. has announced the formation of a clinical & scientific advisory board to support the clinical development of its lead drug candidate RVX-208 and follow-on bromodomain inhibitors in neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment and other dementias.

The board, chaired by Dr. Bengt Winblad, will provide insight and guidance on all aspects of the development program.

"We believe cardiovascular and neurodegenerative health is linked by lipoproteins such as Apolipoprotein A-I (ApoA-I)," said Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix.

Dr. Johansson continued, "A clinical program will further our understanding of how RVX-208, an epigenetic BET bromodomain inhibitor which increases production of Apo A-I, may affect neurodegenerative diseases such as early dementia or mild cognitive impairment."

Donald McCaffrey, president and chief executive officer of Resverlogix, added, "RVX-208 is the first BET bromodomain inhibitor that has emerged from Resverlogix' epigenetic drug discovery platform and moved into the clinic. It is currently in Phase 2b clinical development in patients with high-risk cardiovascular disease and we are eager to evaluate it and our other BET inhibitor compounds in other disease states."

Bengt Winblad, M.D., Ph.D., professor of geriatric medicine and chief physician at the Karolinska University Hospital, said, "Recent studies are providing evidence of the link between poor cognition, memory and low levels of cardio-protective factors such as ApoA-I. I am looking forward to working with Resverlogix and studying RVX-208 in patients with neurodegenerative diseases."

Resverlogix plans to initiate a Phase 2 trial of RVX-208 in patients with mild cognitive impairment in the second half of 2013.

Appointed members of the clinical & scientific advisory board include:
Bengt Winblad, M.D., Chairman: Dr. Winblad is professor of geriatric medicine and chief physician at the Karolinska University Hospital, Huddinge and the Karolinska Institute in Stockholm, Sweden.

Professor Winblad is co-chair of the European Alzheimer Disease Consortium (EADC) and chairs the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI). In 2009, Dr. Winblad was ranked the world's most prolific researcher in the Alzheimer's disease field (J Alzheimer's Disease 2009).

Jeff Cummings, M.D., Sc.D.: Dr. Cummings is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and Cleveland. Dr. Cummings received the Ronald and Nancy Reagan Research Award from the National Alzheimer's Association in 2008.

Henrik Zetterberg, M.D., Ph.D.: Dr. Zetterberg is professor of neurochemistry at the University of Gothenburg. He was a Fulbright Scholar and research fellow in neurology at the Harvard Institutes of Medicine, Boston between 2004 and 2005. Dr. Zetterberg is an established leader in the field of neurochemistry, biomarkers and diagnostics.

Rada Koldamova, M.D., Ph.D.: Dr. Koldamova is an associate professor and lead researcher at the School of Public Health, University of Pittsburgh's Koldamova & Lefterov lab. Her interest is in cellular and molecular mechanisms of neurodegeneration, the role of ABCA1 transporter and apolipoproteins A-I and E in the pathogenesis of Alzheimer's disease.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
First patient randomized in BETonMACE Phase 3 trial in high-risk coronary artery disease and type 2 diabetes mellitus patients.
Tuesday, November 24, 2015
Resverlogix Presents Important New Data at the ASN Kidney Week Conference
Apabetalone and Alkaline Phosphatase data highlighted in multiple presentations.
Saturday, November 21, 2015
Resverlogix Commences Phase 3 Clinical Trial BETonMACE with Apabetalone
Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients.
Saturday, October 31, 2015
Resverlogix Provides Research and Development Update
Company has presented an Update for RVX-208 "apabetalone" on September 25, 2015 in New York City.
Tuesday, October 06, 2015
Resverlogix Announces the Commencement of an Orphan Disease Program
Apabetalone (RVX-208) to be tested in a proof-of-concept pilot trial in a complement mediated disease Paroxysmal Nocturnal Hemoglobinuria (PNH) in 2016.
Saturday, September 26, 2015
Resverlogix Presents New Data at the ESC Congress 2015
Company presents new data on RVX-208 "apabetalone" a selective BET inhibitor.
Tuesday, September 01, 2015
International Clinical Steering Committee Announced from Resverlogix
Professor Kausik Ray to chair clinical steering committee for landmark epigenetic BET inhibition trial.
Saturday, August 08, 2015
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Company expects to launch the upcoming BETonMACE Phase 3 clinical trial.
Tuesday, June 23, 2015
Resverlogix Presents New Data at 52nd Annual ERA-EDTA Congress
RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk.
Thursday, June 04, 2015
Resverlogix and Hepalink Announce a Combination Licensing and Equity Arrangement
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million.
Thursday, May 07, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Donald McCaffrey share developments of the Company's proposed new phase 3 clinical trial BETONMACE.
Thursday, January 15, 2015
Resverlogix Appoints Senior Vice President of Clinical Development
Appointment of Michael T. Sweeney, M.D., as senior vice president.
Tuesday, November 04, 2014
RVX-208 Reduces MACE Significantly in Patients with Diabetes Mellitus
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Thursday, July 24, 2014
Resverlogix Secures an Additional $30 Million from Citibank Loan
Special meeting of shareholders called to approve.
Saturday, July 05, 2014
Resverlogix Granted European Patent
European Patent office grants RVX-208 patent until 2027.
Tuesday, March 18, 2014
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos